

Company registration number: 548142

COPD Support Ireland CLG
(A Company Limited by Guarantee and not having Share Capital)

Financial statements

for the financial year ended 31 December 2022

COPD Support Ireland CLG
(A Company Limited by Guarantee and not having Share Capital)

Contents

	Page
Directors and other information	1 - 2
Directors report	3 - 5
Directors responsibilities statement	6
Independent auditor's report to the members	7 - 10
Income and expenditure account	11
Statement of income and retained earnings	12
Balance sheet	13
Statement of cash flows	14
Notes to the financial statements	15 - 18

COPD Support Ireland CLG
Company limited by guarantee

Directors and other information

Directors	Ciara Hanrahan Michael McGloin (Resigned 27 March 2022) Suzanne McCormack Michael Drohan (Resigned 27 March 2022) Patrick Grimes Sarah O'Beirne Deirdre Garvin Mark O'Kelly (Resigned 27 March 2022) Catherine Craig Marion Hurley Breda Cushen Timothy McDonnell Jacqueline Ho (Appointed 23 February 2022) Eileen Grace (Appointed 23 February 2022) Sue Cleary (Appointed 23 February 2022) Teresa Madden (Appointed 17 October 2022) Richard Hanly (Appointed 17 October 2022) Zoya Ralph (Appointed 17 October 2022) Micahel Coakley (Appointed 17 October 2022)
Secretary	Suzanne McCormack
Company number	548142
Registered office	Workhub 51 Bracken Road Sandyford Business Park Dublin 18 D18 CV48
Business address	Workhub 51 Bracken Road Sandyford Business Park Dublin 18 D18 CV48
Auditor	McCloskey & Co The Glasshouses Unit 16 The Cubes Offices Beacon South Quarter Sandyford Dublin D18 XD36

COPD Support Ireland CLG
Company limited by guarantee

Directors and other information (continued)

Bankers Bank of Ireland
Ballsbridge
Dublin 4

Registered Charity Number 20082512

CHY (Revenue) Number CHY 20731

COPD Support Ireland CLG
(A Company Limited by Guarantee and not having Share Capital)

Directors report

The directors present their annual report and the audited financial statements of the company for the financial year ended 31 December 2022.

Directors and Secretary

The names of the persons who at any time during the financial year were directors of the company are as follows:

Directors

Ciara Hanrahan	Breda Cushen (Appointed 5 May 2021)
Michael McGloin (Resigned 27 March 2022)	Teresa Madden (Appointed 17 October 2022)
Suzanne McCormack	Michael Coakley (Appointed 17 October 2022)
Michael Drohan (Resigned 27 March 2022)	Zoya Ralph (Appointed 17 October 2022)
Patrick Grimes	Richard Hanly (Appointed 17 October 2022)
Sarah O'Beirne	Eileen Grace (Appointed 23 February 2022)
Deirdre Garvin	Jacqueline Ho (Appointed 23 February 2022)
Mark O'Kelly (Resigned 27 March 2022)	Sue Cleary (Appointed 23 February 2022)
Catherine Craig	
Marion Hurley	

Secretary

Suzanne McCormack

Principal activities

The principal activity is to provide assistance and support to people who suffer from chronic pulmonary disease ("COPD"), their carers and families by promoting the development of local support groups, raising awareness of COPD, supporting research and representing the needs of people with COPD at relevant statutory and other agencies.

Development and performance

2022 was a year of overcoming challenges and ultimately the organisation finished the year stronger than it began. While most of our local support groups chose to resume face-to-face weekly peer support and exercise classes, the COVID-19 pandemic remained a concern for many people living with COPD and thus a small number of groups and members chose not to resume meeting in person.

Activities

In 2022 COPDSI delivered 869 weekly exercise classes through in person & online COPD Support & Exercise groups. By the end of 2022, 30 support groups had returned to in person activities or were planning to return in early 2023. In addition to these in-person groups, we delivered 4 virtual COPD support groups, running weekly exercise and peer-to-peer support nationally. COPDSI continued its partnership with SingStrong – Singing for Lung Health through 4 online SingStrong classes each week.

The National Group Representative Forum online meetings took place throughout 2022 at 1 -2 monthly intervals to sustain two-way communication between the national organisation and the local support groups around Ireland. This has been a very useful project and, through direct contact with the groups, the national organisation has been better able to prioritise the support that is needed at the local level. One such priority was a working group of members supported by staff being established to develop a local COPD Support group manual outlining committee roles and responsibilities as well as governance of local group activities in line with the national organisation's governance.

From these meetings and a stakeholder survey, advocacy was highlighted as a key area members felt the organisation could improve on, unfortunately due to staffing constraints, this work had been less of an organisational priority compared to our service delivery in 2022. COPDSI did raise several issues with relevant statutory bodies in collaboration with other organisations such as IPPOSI, the Irish Thoracic Society and the Tobacco 21 alliance. COPDSI continued its participation in the HSE Community Vaccine Network, with a two-way flow of information around the COVID-19 vaccination campaign, infection prevention and control measures and COVID-19 therapeutics. The General

COPD Support Ireland CLG
(A Company Limited by Guarantee and not having Share Capital)

Directors report (continued)

Development and performance (continued)

Manager of COPDSI was a patient partner member of the COVID-19 Therapeutics Advisory group in 2022, this opportunity arose through her role on the Irish Platform for Patient Organisations, Science, and Industry (IPPOSI) Board, as part of the COPDSI membership of that organisation.

Adviceline

COPD Support Ireland continued to support the Asthma Society of Ireland in the delivery of the HSE funded COPD Adviceline in 2022. Tasked to help grow its utilisation in the COPD population, the COPD adviceline was promoted across all public facing media as well as through paid and unpaid World health day and World COPD Day advertising. A COPD Adviceline mail out campaign to Respiratory Consultants was undertaken with COPDSI branded materials including the COPD Adviceline freephone number being included with an information poster and COPD & Me Book. The adviceline was also promoted when we hosted a stand at the Senior Times Live Expo - RDS April 22nd - 24th, co-hosted a stand at the ICGP annual meeting in June with The Asthma Society of Ireland and when we hosted a stand at the Irish Thoracic Society meeting in December 2022.

World COPD Day

World COPD Day activities in 2022 focused on raising awareness through creation and promotion of a series of expert self-management education videos, radio & print media advertising and a PR campaign promoting the ABC (Age, Breathlessness, Cough) of COPD diagnosis.

Additionally, COPD Support Ireland were invited by Mr. Denis Naughten, TD to make a presentation in the Oireachtas AV room on World COPD Day. This presentation was a fantastic opportunity for the organisation to raise awareness about the condition and especially the challenges of living with the condition. We are very grateful to our member, Mr. Ted Hayes, for speaking at this event and eloquently describing his life with this chronic disease as well as highlighting the benefit he receives from weekly attendance at his local COPD support and exercise group. This was a great opportunity for COPDSI to highlight these issues on World COPD Day, which was well attended by TD's, Senators, and staff of the Oireachtas.

Staff & Finance

During 2022, the organisations activities were supported by 2.5 whole-time equivalents comprising 0.5 WTE General Manager, 1 WTE Support Co-ordinator, 0.5 WTE Information and Administration Officer and 0.5 WTE SingStrong Administrator. Three of these 4 posts were funded (either fully or partially) by restricted income grants. Organisational stability remained a concern throughout 2022 as the ability to retain staff at these levels remained uncertain due to the small amount of unrestricted income the organisation generates and the short-term nature of restricted income grants. COPDSI appealed to its member groups and industry partners to support the continued funding of the Support Co-ordinator post following exhaustion of the Comic Relief funding from 2021 in Q2 2022. Fortunately, several partners stepped up and fully funded this post to continue for 12 months. However, there were also several unsuccessful applications such as the SSNO (scheme to support national organisations) multiannual funding and several HSE lottery grant applications, with approximately half the required funding being granted to deliver the weekly support and exercise classes in 2022. In September, COPDSI were faced with the real possibility of having to discontinue delivering these groups in several locations across the country in 2023. Based on this, a comprehensive funding proposal was sent to the HSE in September 2022, and in December 2022 COPD Support Ireland were notified that this proposal was partially successful. The funding secured was to deliver 48 support & exercise groups in 2023. However, this did not include direct funding of any WTE staff, but instead included a contribution towards the administration costs of the organisation. This funding commitment was transformative to the organisation and work will continue in 2023 on securing multiannual funding for the whole of the organisation - activities and staffing.

Conclusion

Overall, 2022 was a year of continued financial and operational challenges for the organisation, however it was also a year that resulted in transformative growth, with the public and professional profile of COPDSI growing significantly through participation on HSE committees and presenting in the AV room of the Oireachtas and mainstream media campaigns. Additionally, there was some progress made in future financial stabilisation and growth achieved through securing HSE funding in 2023 to deliver its core activities of 30 peer to peer support and exercise groups nationally and further grow this number by 18 new groups to deliver 48 groups nationally in 2023.

COPD Support Ireland CLG
(A Company Limited by Guarantee and not having Share Capital)

Directors report (continued)

Financial results, assets and liabilities and financial position

The retained surplus for the financial year amounted to €48,627 (2021: €27,265) and this was transferred to reserves at the year end. At the end of the year the company has assets of €230,085 (2021: €204,216) and liabilities of €101,252-021: €124,012). The net assets of the company are to €128,831 (2021: €80,204).

Total funds in the bank account at the year end was €224,781 which is broken down as follows:

Type	Amount
General reserves	€89,473
Deferred income (restricted)	€91,839
Restricted reserves	€43,469
Total funds in bank	€224,781

Principal risks and uncertainties

The Directors have identified that the key risks and uncertainties the company faces relate to the risk of reduced funding in the future and of the potential increase in compliance requirements in accordance with company, health and safety, taxation and other legislation;

The company mitigates these risks as follows: i) The company continually monitors the level of activity, prepares and monitors its budgets targets and projections. ii) The company closely monitors emerging changes to regulations and legislation on an ongoing basis.

Internal control risks are minimised by the implementation of procedures for authorisation of all transactions and projects. Procedures are in place to ensure compliance with health and safety of staff and volunteers.

Likely future developments

The company plans continuing the activities outlined above in the forthcoming years subject to satisfactory funding arrangements.

Events after the end of the reporting period

There have been no significant events affecting the charity since the year end.

Accounting records

The measures taken by the directors to secure compliance with the requirements of sections 281 to 285 of the Companies Act 2014 with regard to the keeping of accounting records are the implementation of necessary policies and procedures for recording transactions, the employment of competent accounting personnel with appropriate expertise and the provision of adequate resources to the financial function. The accounting records of the company are located at the registered office.

Relevant audit information

In the case of each of the persons who are directors at the time this report is approved in accordance with section 332 of Companies Act 2014:

- so far as each director is aware, there is no relevant audit information of which the company's statutory auditors are unaware, and
- each director has taken all the steps that he or she ought to have taken as a director in order to make himself or herself aware of any relevant audit information and to establish that the company's statutory auditors are aware of that information.

Auditors

In accordance with Section 383 (2) of the Companies Act 2014, McCloskey & Co. have indicated their willingness to continue in office.

This report was approved by the board of directors on 26 July 2023 and signed on behalf of the board by:

Timothy McDonnell
Director

Suzanne McCormack
Director

COPD Support Ireland CLG
(A Company Limited by Guarantee and not having Share Capital)

Directors responsibilities statement

The directors are responsible for preparing the directors report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the directors to prepare financial statements for each financial year. Under the law, the directors have elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" issued by the Financial Reporting Council. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgments and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and directors report comply with the Companies Act 2014 and enable the financial statements to be audited. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The directors are responsible for the maintenance and integrity of the corporate and financial information included on the company's website. Legislation in the Republic of Ireland governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

**Independent auditor's report to the members of
COPD Support Ireland CLG**

Report on the audit of the financial statements

Opinion

We have audited the financial statements of COPD Support Ireland CLG (the 'company') for the financial year ended 31 December 2022 which comprise the profit and loss account, statement of income and retained earnings, balance sheet, statement of cash flows and notes to the financial statements, including a summary of significant accounting policies set out in note 3. The financial reporting framework that has been applied in their preparation is Irish law and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland.

In our opinion, the financial statements:

- give a true and fair view of the assets, liabilities and financial position of the company as at 31 December 2022 and of its profit for the financial year then ended;
- have been properly prepared in accordance with FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland; and
- have been prepared in accordance with the requirements of the Companies Act 2014.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (Ireland) (ISAs (Ireland)) and applicable law. Our responsibilities under those standards are further described in the auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in Ireland, including the Ethical Standard issued by the Irish Auditing and Accounting Supervisory Authority (IAASA), and the provisions available for small entities, in the circumstances set out below, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

As a small entity under the provisions of the IAASA Ethical Standard we engage our auditor to provide basic bookkeeping and accounts preparation.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Company's ability to continue as a going concern for a period of at least twelve months from the date when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

**Independent auditor's report to the members of
COPD Support Ireland CLG (continued)**

Other Information

The directors are responsible for the other information. The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2014

Based solely on the work undertaken in the course of the audit, we report that:

- in our opinion, the information given in the directors' report is consistent with the financial statements; and
- in our opinion, the directors' report has been prepared in accordance with applicable legal requirements.

We have obtained all the information and explanations which we consider necessary for the purposes of our audit.

In our opinion the accounting records of the company were sufficient to permit the financial statements to be readily and properly audited, and financial statements are in agreement with the accounting records.

Matters on which we are required to report by exception

Based on the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the directors' report.

The Companies Act 2014 requires us to report to you if, in our opinion, the disclosures of directors' remuneration and transactions required by sections 305 to 312 of the Act are not made. We have nothing to report in this regard.

Respective responsibilities

Responsibilities of directors for the financial statements

As explained more fully in the directors' responsibilities statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

Independent auditor's report to the members of COPD Support Ireland CLG (continued)

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the management either intends to liquidate the company or to cease operations, or has no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (Ireland) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs (Ireland), we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.
- Conclude on the appropriateness of the directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

The purpose of our audit work and to whom we owe our responsibilities

Our report is made solely to the company's members, as a body, in accordance with section 391 of the Companies Act 2014. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members, as a body, for our audit work, for this report, or for the opinions we have formed.

**Independent auditor's report to the members of
COPD Support Ireland CLG (continued)**

Thomas McCloskey (Senior Statutory Auditor)

For and on behalf of
McCloskey & Co
Chartered Accountants and Registered Auditors
The Glasshouses
Unit 16 The Cubes Offices
Beacon South Quarter
Sandyford
Dublin D18 XD36

26 July 2023

COPD Support Ireland CLG
(A Company Limited by Guarantee and not having Share Capital)

Income and expenditure account
Financial year ended 31 December 2022

	Note	2022	2021
		€	€
Turnover	5	286,316	192,308
Gross surplus		<u>286,316</u>	<u>192,308</u>
Expenditure		(237,689)	(165,043)
Operating surplus	6	<u>48,627</u>	<u>27,265</u>
Surplus before taxation		<u>48,627</u>	<u>27,265</u>
Tax on surplus		-	-
Surplus for the financial year		<u><u>48,627</u></u>	<u><u>27,265</u></u>

All the activities of the company are from continuing operations.

The company has no other recognised items of income and expenses other than the results for the financial year as set out above.

The notes on pages 15 to 18 form part of these financial statements.

COPD Support Ireland CLG
(A Company Limited by Guarantee and not having Share Capital)

Statement of income and retained earnings
Financial year ended 31 December 2022

	2022	2021
	€	€
Surplus for the financial year	48,627	27,265
Retained earnings at the start of the financial year	80,204	52,939
Retained earnings at the end of the financial year	<u>128,831</u>	<u>80,204</u>

COPD Support Ireland CLG
(A Company Limited by Guarantee and not having Share Capital)

Balance sheet
As at 31 December 2022

	Note	2022 €	€	2021 €	€
Fixed assets					
Tangible assets	9	2,899		5,797	
			2,899		5,797
Current assets					
Debtors	10	2,405		-	
Cash at bank and in hand		224,781		198,419	
		227,186		198,419	
Creditors: amounts falling due within one year	11	(101,254)		(124,012)	
Net current assets			125,932		74,407
Total assets less current liabilities			128,831		80,204
Net assets			<u>128,831</u>		<u>80,204</u>
Capital and reserves					
General funds			128,831		80,204
Members funds			<u>128,831</u>		<u>80,204</u>

These financial statements were approved by the board of directors on 26 July 2023 and signed on behalf of the board by:

Timothy McDonnell
Director

Suzanne McCormack
Director

The notes on pages 15 to 18 form part of these financial statements.

COPD Support Ireland CLG
(A Company Limited by Guarantee and not having Share Capital)

Statement of cash flows
Financial year ended 31 December 2022

	2022	2021
	€	€
Cash flows from operating activities		
Surplus for the financial year	48,627	27,265
<i>Adjustments for:</i>		
Depreciation of tangible assets	2,898	2,898
Accrued expenses/(income)	(2,801)	2,926
<i>Changes in:</i>		
Trade and other debtors	(2,405)	-
Trade and other creditors	(19,957)	4,904
Cash generated from operations	<u>26,362</u>	<u>37,993</u>
Net cash from operating activities	<u>26,362</u>	<u>37,993</u>
Cash flows from investing activities		
Purchase of tangible assets	-	(8,695)
Net cash from/(used in) investing activities	<u>-</u>	<u>(8,695)</u>
Net increase/(decrease) in cash and cash equivalents	26,362	29,298
Cash and cash equivalents at beginning of financial year	198,419	169,121
Cash and cash equivalents at end of financial year	<u>224,781</u>	<u>198,419</u>

COPD Support Ireland CLG
(A Company Limited by Guarantee and not having Share Capital)

Notes to the financial statements
Financial year ended 31 December 2022

1. General information

The company is a private company limited by guarantee, registered in Ireland. The address of the registered office is Workhub, 51 Bracken Road, Sandyford Business Park, Dublin 18, D18 CV48.

2. Statement of compliance

These financial statements have been prepared in compliance with FRS 102, 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

3. Accounting policies and measurement bases

Basis of preparation

The financial statements are prepared on the going concern basis, under the historical cost convention and comply with the financial reporting standards of the Financial Reporting Council and promulgated by Chartered Accountants Ireland and the Companies Act 2014.

The financial statements are prepared in Euro, which is the functional currency of the entity.

Turnover

Income consists of donations, fundraising and sponsorship.

Taxation

No charge to current or deferred taxation arises as the company has been granted charitable status under Sections 207 and 208 of the Taxes Consolidation Act 1997, Charity No CHY 20731.

Expenditure

Expenditure is recognised on an accruals basis as a liability is incurred. Expenditure includes any VAT which cannot be fully recovered, and is reported as part of the expenditure to which it relates.

Tangible assets

Tangible assets are initially recorded at cost, and are subsequently stated at cost less any accumulated depreciation and impairment losses.

Depreciation

Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:

Fittings fixtures and equipment - 33%

If there is an indication that there has been a significant change in depreciation rate, useful life or residual value of tangible assets, the depreciation is revised prospectively to reflect the new estimates.

Impairment

A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date.

COPD Support Ireland CLG
(A Company Limited by Guarantee and not having Share Capital)

Notes to the financial statements (continued)
Financial year ended 31 December 2022

Departure from Companies Act 2014 presentation

The directors have elected to present an Income and Expenditure Account instead of a Profit and Loss Account in these financial statements as this company is a not-for-profit entity.

4. Limited by guarantee

The liability of the members is limited. Every member of the company undertakes to contribute to the assets of the company in the event of its being wound up while they are members, or within one year thereafter, for the payment of the debts and liabilities of the company contracted before they ceased to be members, and of the costs, charges and expenses of winding up, and for the adjustment of the rights of the contributors among themselves, such amount as may be required, not exceeding € 2.00 (Two Euro).

5. Turnover

Turnover arises from:

	2022	2021
	€	€
Fundraising Event Income	90	1,524
General Donations	30,148	17,616
Corporate Donations	57,376	57,546
World COPD Day	37,000	47,500
Membership	980	70
HSE Chronic Disease programme	20,000	-
Other income	60,013	-
HSE Lottery Funding	71,211	17,157
Comic Relief	9,498	50,895
	286,316	192,308
	286,316	192,308

The whole of the turnover is attributable to the principal activity of the company which is wholly undertaken in Ireland.

6. Operating surplus

Operating surplus is stated after charging/(crediting):

	2022	2021
	€	€
Depreciation of tangible assets	2,898	2,898
	2,898	2,898
	2,898	2,898

COPD Support Ireland CLG
(A Company Limited by Guarantee and not having Share Capital)

Notes to the financial statements (continued)
Financial year ended 31 December 2022

7. Staff costs

The average number of persons employed by the company during the financial year, including the directors, was as follows:

	2022	2021
	Number	Number
Administrative	3	3
	<u> </u>	<u> </u>

The aggregate payroll costs incurred during the financial year were:

	2022	2021
	€	€
Wages and salaries	72,422	65,853
Social insurance costs	7,416	7,081
	<u> </u>	<u> </u>
	<u>79,838</u>	<u>72,934</u>

8. Appropriations of income and expenditure account

	2022	2021
	€	€
At the start of the financial year	80,204	52,939
Surplus for the financial year	48,627	27,265
	<u> </u>	<u> </u>
At the end of the financial year	<u>128,831</u>	<u>80,204</u>

9. Tangible assets

	Fixtures, fittings and equipment	Total
	€	€
Cost		
At 1 January 2022 and 31 December 2022	8,695	8,695
	<u> </u>	<u> </u>
Depreciation		
At 1 January 2022	2,898	2,898
Charge for the financial year	2,898	2,898
	<u> </u>	<u> </u>
At 31 December 2022	<u>5,796</u>	<u>5,796</u>
Carrying amount		
At 31 December 2022	2,899	2,899
	<u> </u>	<u> </u>
At 31 December 2021	5,797	5,797
	<u> </u>	<u> </u>

COPD Support Ireland CLG
(A Company Limited by Guarantee and not having Share Capital)

Notes to the financial statements (continued)
Financial year ended 31 December 2022

10. Debtors

	2022	2021
	€	€
Prepayments	2,405	-
	<u>2,405</u>	<u>-</u>

11. Creditors: amounts falling due within one year

	2022	2021
	€	€
Trade creditors	5,740	135
Tax and social insurance: PAYE and social welfare	1,688	-
Accruals	1,988	4,789
Deferred income	91,838	119,088
	<u>101,254</u>	<u>124,012</u>

12. Analysis of changes in net debt

	At 1 January 2022	Cash flows	At 31 December 2022
	€	€	€
Cash and cash equivalents	198,419	26,362	224,781
	<u>198,419</u>	<u>26,362</u>	<u>224,781</u>

13. Events after the end of the reporting period

There have been no significant events affecting the charity since the year end.

14. Ethical standards

As a small entity under the provisions of the IAASA Ethical Standard we engage our auditor to provide basic bookkeeping and accounts preparation.

15. Approval of financial statements

The board of directors approved these financial statements for issue on 26 July 2023.

COPD Support Ireland CLG
(A Company Limited by Guarantee and not having Share Capital)

The following pages do not form part of the statutory accounts.

COPD Support Ireland CLG
(A Company Limited by Guarantee and not having Share Capital)

Detailed income and expenditure account
Financial year ended 31 December 2022

	2022	2021
	€	€
Turnover		
Fundraising Event Income	90	1,524
General Donations	30,148	17,616
Corporate Funding	38,353	26,749
World COPD Day	37,000	47,500
Membership	980	70
HSE Lottery funding	71,211	17,157
Rethink Ireland Ignite Midwest Fund	19,023	30,797
Other income	60,013	-
HSE Chronic Disease programme	20,000	-
Comic Relief	9,498	50,895
	<u>286,316</u>	<u>192,308</u>
Gross surplus	<u>286,316</u>	<u>192,308</u>
Gross surplus percentage	100.0%	100.0%
Overheads		
Administrative expenses		
Wages and salaries	(72,422)	(65,853)
Employer's PRSI contributions	(7,416)	(7,081)
Programme expenses	(115,565)	(59,512)
Insurance	(1,971)	(2,362)
Printing, postage and stationery	(11,843)	(6,595)
Website costs	(7,652)	(9,657)
Telephone	(1,405)	(2,085)
Motor expenses	(62)	-
Legal and professional	(12,779)	(5,618)
Auditors remuneration	(1,950)	(1,968)
Bank charges	(305)	(505)
General expenses	(21)	(634)
Subscriptions	(1,400)	(275)
Depreciation of tangible assets	(2,898)	(2,898)
	<u>(237,689)</u>	<u>(165,043)</u>
Operating surplus	48,627	27,265
Operating surplus percentage	17.0%	14.2%
Surplus before taxation	<u>48,627</u>	<u>27,265</u>